Title

Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    285
Randomized phase III trial to compare the effectiveness of immediate adjuvant chemotherapy with that of adjuvant chemotherapy given when the cancer returns in treating patients who have undergone a radical cystectomy for stage III or stage IV transitional cell carcinoma of the bladder urothelium. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known if adjuvant chemotherapy is more effective when given immediately after radical cystectomy (surgery to remove the bladder) or when the cancer returns.
PRIMARY OBJECTIVES:

I. Compare the overall and progression-free survival of patients with stage III or IV transitional cell carcinoma of the bladder urothelium treated with immediate versus deferred adjuvant chemotherapy after radical cystectomy.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, tumor status (pT1-2 vs pT3 vs pT4), and node status (node positive vs node negative with 15 or more nodes sampled vs node negative with less than 15 nodes sampled). Patients are randomized to one of two treatment arms.

ARM I: Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.

ARM II: Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.

Patients in both arms receive one of the following chemotherapy regimens to be determined by participating center:

REGIMEN A (Classical M-VAC): Patients receive classical M-VAC comprising methotrexate IV on days 1, 15 and 22; vinblastine IV on days 2, 15, and 22; and doxorubicin IV and cisplatin IV on day 2. Courses repeat every 28 days.

REGIMEN B (High-dose M-VAC): Patients receive high-dose M-VAC comprising methotrexate IV on day 1 and vinblastine IV, doxorubicin IV, and cisplatin IV on day 2. Patients also receive filgrastim (G-CSF subcutaneously once daily on days 4-10. Courses repeat every 14 days.

REGIMEN C (Gemcitabine and cisplatin): Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 followed by cisplatin IV on day 1 or 2. Courses repeat every 28 days.

Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK and EORTC.
Study Started
Oct 31
2001
Primary Completion
Jan 31
2014
Study Completion
Jul 31
2014
Last Update
Aug 02
2016
Estimate

Drug doxorubicin hydrochloride

Given IV

  • Other names: ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF

Drug gemcitabine hydrochloride

Given IV

  • Other names: dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar

Drug vinblastine sulfate

Given IV

  • Other names: 29060-LE, Exal, Velban, Velbe, Velsar

Drug methotrexate

Given IV

  • Other names: amethopterin, Folex, methylaminopterin, Mexate, MTX

Drug cisplatin

Given IV

  • Other names: CACP, CDDP, CPDD, DDP

Biological filgrastim

Given SC

  • Other names: Neupogen, G-CSF

Arm I (immediate chemotherapy) Active Comparator

Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.

Arm II (deferred chemotherapy) Experimental

Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.

Criteria

Inclusion Criteria:

Histologically confirmed transitional cell carcinoma of the bladder urothelium

T3-4, N1-3, M0
No pure squamous cell or adenocarcinoma tumors
No more than 90 days since prior radical cystectomy and bilateral lymphadenectomy without evidence of microscopic residual disease
Performance status - WHO 0-1
WBC at least 3,500/mm^3
Platelet count at least 120,000/mm^3
SGOT/SGPT less than 2.5 times upper limit of normal (ULN)
Alkaline phosphatase less than 2.5 times ULN
Bilirubin normal
Glomerular filtration rate greater than 60 mL/min
No clinically significant cardiac arrhythmia
No congestive heart failure
No complete bundle branch block
No New York Heart Association class III or IV heart disease
Not pregnant or nursing
Fertile patients must use effective contraception during and for 6 months after study
Considered fit for cisplatin-containing combination chemotherapy
No clinically abnormal auditory function
No known hypersensitivity to E. coli-derived drug preparations
No grade 2 or greater peripheral neuropathy
No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix, treated basal cell skin cancer, or treated incidental prostate cancer (pT2, Gleason score no greater than 6, and PSA less than 0.5 ng/mL)
No psychological, familial, sociological, or geographical condition that would preclude study involvement
No prior systemic chemotherapy
No prior radiotherapy to the bladder
No Results Posted